Values Added Financial LLC Has $250,000 Holdings in Johnson & Johnson (NYSE:JNJ)

Values Added Financial LLC raised its stake in Johnson & Johnson (NYSE:JNJFree Report) by 8.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,593 shares of the company’s stock after acquiring an additional 119 shares during the quarter. Values Added Financial LLC’s holdings in Johnson & Johnson were worth $250,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in JNJ. FIDELIS iM LLC raised its stake in Johnson & Johnson by 3.1% during the fourth quarter. FIDELIS iM LLC now owns 2,117 shares of the company’s stock worth $374,000 after acquiring an additional 64 shares in the last quarter. Clearview Wealth Advisors LLC raised its stake in Johnson & Johnson by 1.5% during the fourth quarter. Clearview Wealth Advisors LLC now owns 4,373 shares of the company’s stock worth $685,000 after acquiring an additional 64 shares in the last quarter. TFG Advisers LLC increased its stake in shares of Johnson & Johnson by 0.4% in the third quarter. TFG Advisers LLC now owns 18,330 shares of the company’s stock valued at $2,855,000 after buying an additional 67 shares during the period. My Legacy Advisors LLC increased its stake in shares of Johnson & Johnson by 3.1% in the fourth quarter. My Legacy Advisors LLC now owns 2,222 shares of the company’s stock valued at $358,000 after buying an additional 67 shares during the period. Finally, Kellett Wealth Advisors LLC increased its stake in shares of Johnson & Johnson by 3.8% in the third quarter. Kellett Wealth Advisors LLC now owns 1,880 shares of the company’s stock valued at $293,000 after buying an additional 68 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on JNJ. Raymond James upped their price objective on Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a research note on Wednesday, January 3rd. Morgan Stanley lowered their price objective on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a research note on Wednesday, January 24th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. Wells Fargo & Company cut Johnson & Johnson from an “overweight” rating to an “equal weight” rating and reduced their target price for the company from $170.00 to $163.00 in a report on Wednesday, December 13th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, March 13th. Seven equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $177.31.

Check Out Our Latest Report on JNJ

Insider Buying and Selling

In related news, major shareholder & Johnson Johnson sold 3,725 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the transaction, the insider now directly owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, major shareholder & Johnson Johnson sold 3,725 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the transaction, the insider now directly owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Jennifer L. Taubert sold 59,397 shares of the stock in a transaction on Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the sale, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $158.19 on Friday. The stock has a market capitalization of $381.20 billion, a price-to-earnings ratio of 11.45, a PEG ratio of 2.66 and a beta of 0.53. Johnson & Johnson has a 52-week low of $144.95 and a 52-week high of $175.97. The stock’s 50 day moving average price is $158.58 and its two-hundred day moving average price is $156.67. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.91 and a current ratio of 1.16.

Johnson & Johnson (NYSE:JNJGet Free Report) last posted its quarterly earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.28 by $0.01. Johnson & Johnson had a return on equity of 37.27% and a net margin of 37.79%. The firm had revenue of $21.40 billion for the quarter, compared to analysts’ expectations of $21.02 billion. During the same period in the prior year, the business earned $2.35 EPS. The company’s revenue for the quarter was down 9.7% compared to the same quarter last year. On average, equities analysts predict that Johnson & Johnson will post 10.65 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, March 5th. Investors of record on Tuesday, February 20th were issued a $1.19 dividend. This represents a $4.76 dividend on an annualized basis and a dividend yield of 3.01%. The ex-dividend date was Friday, February 16th. Johnson & Johnson’s dividend payout ratio is currently 34.47%.

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Recommended Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.